<DOC>
	<DOC>NCT01921127</DOC>
	<brief_summary>This study is intended to evaluate treatment effectiveness of BFC compared to FSC in COPD patients new to ICS/LABA combination therapy.</brief_summary>
	<brief_title>Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Continuous health plan enrollment for 12 months before and after index Rx, at least one prescription for BFC or FSC during intake period, naive to ICS/LABA therapies in year prior to first prescription claim, COPD diagnosis, aged 40 or over at time of first prescription. ICS/LABA combination during preindex period, patients with a claim for BFC and FSC on the same day, patients diagnosed with cancer, patients with longterm OCS medication use during preindex period.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>COPD, Comparative effectiveness, Symbicort</keyword>
</DOC>